and rs7270101 polymorphisms may result in reducing the activity of the ITPase enzyme and subsequent accumulation of ITP and protecting against adenosine triphosphate (ATP) reduction in erythrocytes. 6, 7 The rs1127354 and 7270101 polymorphisms have 3 genotypes CC, CA, and AA in which wild-type CC (rs1127354) and wild-type AA (rs7270101) follow by complete activity of ITPase; wild-type CC (rs1127354) and heterozygous AC (rs7270101) follow by 60% activity; heterozygous CA (rs1127354) and wild-type AA (rs7270101), wild-type CC (rs1127354) and homozygous CC (rs7270101) follow by 30%; heterozygous CA (rs1127354) and heterozygous AC (rs7270101) follow by 10% activity; and homozygous AA (rs1127354) and wild-type AA (rs7270101) follow by no activity to ITPase. 8, 9 Mutated ITPA gene is considered as a symptom of benign enzyme disorder. 10, 11 This benign disorder leads to the accumulation of ITP in the red blood cells (RBC). It has been determined that ITP can be used as an alternative to GTP in ATP biosynthesis. This will lead to the resistance of those carrying the ITPA variant to anemia and severe hemoglobin decrease following RBV-related treatments. 12 Ribavirin is known as a purine nucleoside analogue and one of the fundamental treatments of chronic hepatitis C. 4, 13, 14 The ITPase activity may lead to anemia induction via endogenous purines. 4 Hemolytic anemia, as one of the major side effects of pegylated-interferon/RBV therapy, affects 30% of chronic HCV-infected patients. [15] [16] [17] Interactions between RBV and intracellular concentrations of GTP and, as a result, ATP levels in RBCs lead to RBV-induced anemia. 18 Ribavirin decreases the ATP levels followed by GTP decline when enters to the leukocytes and ultimately causes oxidative stress and lysis of RBCs, and subsequently, hemolytic anemia occurs. 19 Studies showed that ITPA gene variations are determining factors for protection against RBV-induced anemia. 9, 20 In 2014, Hai and colleagues investigated the relationship between ITPA genotypes and hepatitis C treatment outcomes. They asserted that ITPA rs1127354 is a predictive factor for determining sustained viral response (SVR) in patients with hepatitis C and prognosis factor of RBV post-treatment anemia. 21 Hence, we assessed the rs1127354 and rs7270101 genotyping for the detection of ITPA gene polymorphisms and the main purpose of our study was to establish a PCR-RFLP method as a rapid and costeffective technique for genotyping of ITPA gene polymorphisms.
| MATERIAL AND ME THODS

| Study population
In this study, 100 patients with chronic hepatitis C (93 males and 7 females) were examined. Patients having HCV antibody and HCV RNA for more than 6 months were considered as chronic HCVinfected patients. These patients were referred periodically to the Armin Pathobiology Laboratory (Tehran, Iran). According to sterile conditions, 5 mL of blood samples was collected and centrifuged at 1000 × g for 10 minutes. Buffy coat of samples was separated and transferred to 1.5-mL sterile tubes. The samples were quickly stored at −20°C and were kept frozen until further examinations.
It should be noted that patients were negative for viral infections including HIV or other hepatitis viruses.
| ITPA Genotyping by PCR-RFLP
According to manufacturer's instructions, DNA of buffy coat from venous blood samples was extracted using QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The extracted DNA samples were stored at −20°C until later experiments.
The PCR products were performed using ready-to-use Taq R-5′-CCGGCTCCCCCTGGTACTCC-3′ 66 TM, melting temperature; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reactionrestriction fragment length polymorphism; bp, base pair. TM calculation of primers was performed using the Santa Lucia formula. *The third nucleotide in 3′ end of the RFLP-R primer is mismatch nucleotide which is shown by an underline.
TA B L E 1
The specific primers for genotyping of ITPA gene polymorphisms by PCR-RFLP and PCR sequencing
| ITPA genotyping via PCR sequencing
The amount of PCR materials including master mix, forward and reverse primers for sequencing as listed in Table 1 
| Validation protocol
To validate the genotyping methods of ITPA rs7270101 and rs1127354 polymorphisms, both techniques of PCR-RFLP and sequencing should be 100% concordant. 
| RE SULTS
| ITPA genomic region and the primer design
that the nucleotide sequence containing rs1127354 A allele is recognized by XceI restriction enzyme with recognition site of
5′-RCATGY-3′ and also MboII targets rs7270101 polymorphism
and cuts at 5′-GAAGA-3′. We introduced a mutation in 3 nucleotides downstream of rs7270101 using a mismatch in RFLP-R primer as presented in Figure 1 . With the mentioned change in the PCR product, the MboII restriction enzyme would digest the allele C of rs7270101, while the allele A will not be digested using
MboII. To obtain better results in the PCR-RFLP technique, the reverse primer was selected slightly longer. The characteristics of primers are specified in Table 1 .
| The PCR-RFLP results
Treatment with XceI restriction enzyme for rs1127354 and MboII restriction enzyme for rs7270101 was conducted for more than 
| The PCR-sequencing results
The rs1127354 and rs7270101 polymorphisms were nucleotides of 208 and 259 from the 5′ end of the forward sequencing primer, respectively. Figure 3 represents chromatograms of the sequences and the given genotypes.
| Validation results
Based on PCR-RFLP method, genotypic frequency of rs7270101 polymorphism was as follows: 80% AA, 19% AC, and 1% CC and these results for rs1127354 polymorphism were as follows: 79% CC, 20% CA, and 1% AA. The both PCR-RFLP and sequencing results were 100% concordant. showed that among 405 patients the CC genotype was present in 66.4% of patients and 33.6% had the AA or the CA allelic variants ("AA or CA" as a combo variable) at rs1127354. ITPA polymorphism can influence hemoglobin levels and sustained virological response (SVR) rates and also the incidence of RBV dose reduction in Sofosbuvir plus RBV treatment. 24, 25 These studies all agree on the effect of rs1127354, as a recessive allele, which is a protective factor against post-treatment anemia. In the study of Sharafi et al 28 on IL28B polymorphism to evaluate the response to hepatitis C treatment, they showed that the PCR-RFLP technique was convenient to use and inexpensive.
However, the method of sequencing is a standard and validated, but it is expensive and requires experienced technician. 29 The PCR-RFLP technique used in this study to detect rs1127354 and rs7270101 polymorphisms of ITPA gene is up to date and also inexpensive compared to other techniques. Regarding the history of the previous research, we decided to perform PCR-RFLP and sequencing techniques to determine the rs1127354 and rs7270101 polymorphism of ITPA gene. 28 In conclusion, we compared the two techniques to find the appropriate method. The result showed that all the 100 samples tested with PCR-RFLP technique and sequencing have exactly the same results. As sequencing method is a standard method, comparison with this method has shown that the PCR-RFLP is a reliable and acceptable technique and is proposed to reduce the costs in studies requiring an examination of the ITPA gene polymorphisms. 
AUTH O R CO NTR I B UTI O N S
